Home > News > Headline News > Archive

Click on title to read the full article.

Study Finds Death Risk From Anemia Drugs

February 28, 2008

Widely used anemia drugs sold by Amgen and Johnson & Johnson raise the risk of death among cancer patients by about 10 percent, according to a new analysis of previous clinical trials that is to be published Wednesday.

The study is the first compilation of clinical trial data — called a meta-analysis — to show a statistically significant increase in the risk of death from the drugs, said Dr. Charles L. Bennett, a professor at Northwestern University and its lead author. 

New Anti-cancer Agent Can Overcome Drug Resistance, Says Study

February 26, 2008

By Science Daily

 A new anti-cancer agent that targets breast cancer can overcome resistance to cancer drugs, according to a new study by the Imperial College London.

Many tumours that are initially responsive to chemotherapy can develop resistance to it, allowing the cancer to progress. Studies have shown that one of the key reasons for the development of resistance is a protein pump called P-glycoprotein. Resistant cancer cells express P-glycoprotein and this removes anti-cancer drugs from the cell before they are able to kill the cell.

The new study shows that P-glycoprotein is not able to remove a recently identified anti-cancer agent known as STX140 from cancer cells. STX140 works by stimulating a natural cell suicide process and is able to kill cancer cells which express the P-glycoprotein pump.

Avastin OK’d for breast cancer

February 23, 2008

By Daniel Costello, LA Times

FDA approves the drug’s use despite a lack of evidence that it extends patients’ lives.

In a surprise decision that could portend significant changes in how federal regulators approve cancer drugs, the Food and Drug Administration Friday approved the use of a $100,000-a-year drug for use by women with breast cancer although there is little evidence it helps breast cancer patients live longer.

Avastin, manufactured by South San Francisco-based biotech giant Genentech Inc., is already a blockbuster cancer drug used to treat advanced colon and lung cancer. Research shows the drug slows the progress of breast cancer tumors by more than five months but does not extend patients’ lives.

FDA Nears Ruling on Avastin for Breast Cancer

February 21, 2008

By Wall Street Journal

FDA is close to ruling on Avastin for Breast Cancer.

Genentech Inc.’s push to market Avastin for breast cancer has split the cancer community, which remains divided despite an 11th-hour boost last week from news of a study involving the drug by Genentech’s majority shareholder, Roche Holding AG.

The FDA is due to decide on Avastin by Saturday, but the outcome is far from assured. Members of an agency advisory committee voted 5-4 against approval in December. While the FDA isn’t required to follow the panel’s recommendations, it usually does. European regulatory authorities approved Avastin for breast cancer last March.

New Phase 2b Clinical Trial for MBC Patients treated with Avastin(R)

February 16, 2008

By MedicalNewsToday.com

Accelerated Community Oncology Research Network, Inc. (ACORN), announced the initiation of a Phase 2b clinical trial evaluating the efficacy of Nexavar(R) (sorafenib) tablets in combination with the anticancer drug gemcitabine (Gemzar(R)) in patients with metastatic breast cancer whose cancer has progressed during or after treatment with bevacizumab (Avastin(R)).

The double-blind, randomized trial will enroll a total of 220 patients at approximately 45 sites in approximately 20 states and will assess efficacy, safety and patient quality of life as endpoints. Patients will be randomly assigned to receive either Nexavar and gemcitabine, or placebo and gemcitabine.

Genentech’s Avastin does well in breast cancer test

February 14, 2008

By SanFrancisco Business Times

Genentech Inc. said Tuesday that its drug Avastin did well in a Phase III trial in combination with another treatment against breast cancer.

Neuroscientists Offer Hope For Breast Cancer Patients Suffering From ‘Chemobrain’

February 9, 2008

By MedicalNewsToday.com

Mental function in cancer patients with “chemobrain” can be improved by training with the Posit Science (R) Brain Fitness Program.  The data will be presented by researchers at the International Neuropsychological Society’s annual meeting.

Nineteen breast cancer patients, all women, who underwent chemotherapy and reported having “chemobrain” participated in the study.

Tumor-Specific Imaging for Breast Cancer at Thomas Jefferson University

February 7, 2008

By PR Newswire

PARK CITY, Utah -- NuView Radiopharmaceuticals, Inc. (NuView) has executed an agreement with Thomas Jefferson University (Jefferson) for the exclusive distribution and commercialization rights for a tumor-specific imaging agent that assists in the diagnosis of breast and prostate tumors. NuView also intends to sponsor research at Jefferson to further develop the technology.

Resistance To Breast Cancer Treatment Determined By Unsuspected Protein

February 6, 2008

By ScienceDaily

An innovative research approach has identified a previously unsuspected protein as a key player in the resistance to particular forms of breast cancer therapy. The study, published by Cell Press in the February issue of Cancer Cell, significantly advances the understanding of the molecular response to breast cancer therapies that target estrogen signaling.

Epoetin Beta Has Little Effect in Metastatic Breast Cancer

February 5, 2008

By ModernMedicine.com

In patients with metastatic breast cancer who receive anthracycline- and/or taxane-based chemotherapy and develop anemia, epoetin beta increases hemoglobin levels but does not improve overall survival, researchers report in the Feb. 1 issue of the Journal of Clinical Oncology.